

Anti-Hypertensive Drugs-EMEA Market Status and Trend Report 2013-2023

https://marketpublishers.com/r/A22FE6FC39AEN.html

Date: December 2017

Pages: 147

Price: US\$ 3,480.00 (Single User License)

ID: A22FE6FC39AEN

Abstracts

Report Summary

Anti-Hypertensive Drugs-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Anti-Hypertensive Drugs industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole EMEA and Regional Market Size of Anti-Hypertensive Drugs 2013-2017, and development forecast 2018-2023

Main market players of Anti-Hypertensive Drugs in EMEA, with company and product introduction, position in the Anti-Hypertensive Drugs market

Market status and development trend of Anti-Hypertensive Drugs by types and applications

Cost and profit status of Anti-Hypertensive Drugs, and marketing status Market growth drivers and challenges

The report segments the EMEA Anti-Hypertensive Drugs market as:

EMEA Anti-Hypertensive Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Europe Middle East Africa



EMEA Anti-Hypertensive Drugs Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Diuretics

Angiotensin Converting Enzyme (ACE) Inhibitors

Angiotensin Receptor Blockers (ARBs)

Calcium Channel Blockers

Beta Blockers

Alpha Blockers

Vasodilators

Renin Inhibitors

EMEA Anti-Hypertensive Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

EMEA Anti-Hypertensive Drugs Market: Players Segment Analysis (Company and Product introduction, Anti-Hypertensive Drugs Sales Volume, Revenue, Price and Gross Margin):

Novartis

Pfizer

Johnson & Johnson

Sanofi

Lupin

Ranbaxy Laboratories

Merck

AstraZeneca

Daiichi Sankyo Company Limited

Takeda Pharmaceutical

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.



Contents

CHAPTER 1 OVERVIEW OF ANTI-HYPERTENSIVE DRUGS

- 1.1 Definition of Anti-Hypertensive Drugs in This Report
- 1.2 Commercial Types of Anti-Hypertensive Drugs
 - 1.2.1 Diuretics
 - 1.2.2 Angiotensin Converting Enzyme (ACE) Inhibitors
 - 1.2.3 Angiotensin Receptor Blockers (ARBs)
 - 1.2.4 Calcium Channel Blockers
 - 1.2.5 Beta Blockers
 - 1.2.6 Alpha Blockers
 - 1.2.7 Vasodilators
- 1.2.8 Renin Inhibitors
- 1.3 Downstream Application of Anti-Hypertensive Drugs
 - 1.3.1 Hospital Pharmacies
 - 1.3.2 Retail Pharmacies
 - 1.3.3 Online Pharmacies
- 1.4 Development History of Anti-Hypertensive Drugs
- 1.5 Market Status and Trend of Anti-Hypertensive Drugs 2013-2023
 - 1.5.1 EMEA Anti-Hypertensive Drugs Market Status and Trend 2013-2023
 - 1.5.2 Regional Anti-Hypertensive Drugs Market Status and Trend 2013-2023

CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Anti-Hypertensive Drugs in EMEA 2013-2017
- 2.2 Consumption Market of Anti-Hypertensive Drugs in EMEA by Regions
 - 2.2.1 Consumption Volume of Anti-Hypertensive Drugs in EMEA by Regions
 - 2.2.2 Revenue of Anti-Hypertensive Drugs in EMEA by Regions
- 2.3 Market Analysis of Anti-Hypertensive Drugs in EMEA by Regions
 - 2.3.1 Market Analysis of Anti-Hypertensive Drugs in Europe 2013-2017
 - 2.3.2 Market Analysis of Anti-Hypertensive Drugs in Middle East 2013-2017
 - 2.3.3 Market Analysis of Anti-Hypertensive Drugs in Africa 2013-2017
- 2.4 Market Development Forecast of Anti-Hypertensive Drugs in EMEA 2018-2023
 - 2.4.1 Market Development Forecast of Anti-Hypertensive Drugs in EMEA 2018-2023
- 2.4.2 Market Development Forecast of Anti-Hypertensive Drugs by Regions 2018-2023

CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES



- 3.1 Whole EMEA Market Status by Types
- 3.1.1 Consumption Volume of Anti-Hypertensive Drugs in EMEA by Types
- 3.1.2 Revenue of Anti-Hypertensive Drugs in EMEA by Types
- 3.2 EMEA Market Status by Types in Major Countries
 - 3.2.1 Market Status by Types in Europe
 - 3.2.2 Market Status by Types in Middle East
 - 3.2.3 Market Status by Types in Africa
- 3.3 Market Forecast of Anti-Hypertensive Drugs in EMEA by Types

CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Demand Volume of Anti-Hypertensive Drugs in EMEA by Downstream Industry
- 4.2 Demand Volume of Anti-Hypertensive Drugs by Downstream Industry in Major Countries
- 4.2.1 Demand Volume of Anti-Hypertensive Drugs by Downstream Industry in Europe
- 4.2.2 Demand Volume of Anti-Hypertensive Drugs by Downstream Industry in Middle East
- 4.2.3 Demand Volume of Anti-Hypertensive Drugs by Downstream Industry in Africa
- 4.3 Market Forecast of Anti-Hypertensive Drugs in EMEA by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF ANTI-HYPERTENSIVE DRUGS

- 5.1 EMEA Economy Situation and Trend Overview
- 5.2 Anti-Hypertensive Drugs Downstream Industry Situation and Trend Overview

CHAPTER 6 ANTI-HYPERTENSIVE DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA

- 6.1 Sales Volume of Anti-Hypertensive Drugs in EMEA by Major Players
- 6.2 Revenue of Anti-Hypertensive Drugs in EMEA by Major Players
- 6.3 Basic Information of Anti-Hypertensive Drugs by Major Players
- 6.3.1 Headquarters Location and Established Time of Anti-Hypertensive Drugs Major Players
- 6.3.2 Employees and Revenue Level of Anti-Hypertensive Drugs Major Players
- 6.4 Market Competition News and Trend
 - 6.4.1 Merger, Consolidation or Acquisition News



- 6.4.2 Investment or Disinvestment News
- 6.4.3 New Product Development and Launch

CHAPTER 7 ANTI-HYPERTENSIVE DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

- 7.1 Novartis
 - 7.1.1 Company profile
 - 7.1.2 Representative Anti-Hypertensive Drugs Product
 - 7.1.3 Anti-Hypertensive Drugs Sales, Revenue, Price and Gross Margin of Novartis
- 7.2 Pfizer
 - 7.2.1 Company profile
 - 7.2.2 Representative Anti-Hypertensive Drugs Product
 - 7.2.3 Anti-Hypertensive Drugs Sales, Revenue, Price and Gross Margin of Pfizer
- 7.3 Johnson & Johnson
 - 7.3.1 Company profile
 - 7.3.2 Representative Anti-Hypertensive Drugs Product
- 7.3.3 Anti-Hypertensive Drugs Sales, Revenue, Price and Gross Margin of Johnson & Johnson
- 7.4 Sanofi
 - 7.4.1 Company profile
 - 7.4.2 Representative Anti-Hypertensive Drugs Product
- 7.4.3 Anti-Hypertensive Drugs Sales, Revenue, Price and Gross Margin of Sanofi
- 7.5 Lupin
 - 7.5.1 Company profile
 - 7.5.2 Representative Anti-Hypertensive Drugs Product
- 7.5.3 Anti-Hypertensive Drugs Sales, Revenue, Price and Gross Margin of Lupin
- 7.6 Ranbaxy Laboratories
 - 7.6.1 Company profile
 - 7.6.2 Representative Anti-Hypertensive Drugs Product
- 7.6.3 Anti-Hypertensive Drugs Sales, Revenue, Price and Gross Margin of Ranbaxy Laboratories
- 7.7 Merck
 - 7.7.1 Company profile
 - 7.7.2 Representative Anti-Hypertensive Drugs Product
- 7.7.3 Anti-Hypertensive Drugs Sales, Revenue, Price and Gross Margin of Merck
- 7.8 AstraZeneca
 - 7.8.1 Company profile
- 7.8.2 Representative Anti-Hypertensive Drugs Product



- 7.8.3 Anti-Hypertensive Drugs Sales, Revenue, Price and Gross Margin of AstraZeneca
- 7.9 Daiichi Sankyo Company Limited
 - 7.9.1 Company profile
 - 7.9.2 Representative Anti-Hypertensive Drugs Product
- 7.9.3 Anti-Hypertensive Drugs Sales, Revenue, Price and Gross Margin of Daiichi Sankyo Company Limited
- 7.10 Takeda Pharmaceutical
 - 7.10.1 Company profile
 - 7.10.2 Representative Anti-Hypertensive Drugs Product
- 7.10.3 Anti-Hypertensive Drugs Sales, Revenue, Price and Gross Margin of Takeda Pharmaceutical

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF ANTI-HYPERTENSIVE DRUGS

- 8.1 Industry Chain of Anti-Hypertensive Drugs
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF ANTI-HYPERTENSIVE DRUGS

- 9.1 Cost Structure Analysis of Anti-Hypertensive Drugs
- 9.2 Raw Materials Cost Analysis of Anti-Hypertensive Drugs
- 9.3 Labor Cost Analysis of Anti-Hypertensive Drugs
- 9.4 Manufacturing Expenses Analysis of Anti-Hypertensive Drugs

CHAPTER 10 MARKETING STATUS ANALYSIS OF ANTI-HYPERTENSIVE DRUGS

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
 - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy
 - 10.2.3 Target Client
- 10.3 Distributors/Traders List



CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
 - 12.1.1 Research Programs/Design
 - 12.1.2 Market Size Estimation
 - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
 - 12.2.1 Secondary Sources
 - 12.2.2 Primary Sources
- 12.3 Reference



I would like to order

Product name: Anti-Hypertensive Drugs-EMEA Market Status and Trend Report 2013-2023

Product link: https://marketpublishers.com/r/A22FE6FC39AEN.html

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/A22FE6FC39AEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970